Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Chronic Obstructive Pulmonary Disease Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Chronic Obstructive Pulmonary Disease Drugs Industry
  • 1.7 COVID-19 Impact: Chronic Obstructive Pulmonary Disease Drugs Market Trends

    • 2 Global Chronic Obstructive Pulmonary Disease Drugs Quarterly Market Size Analysis

    • 2.1 Chronic Obstructive Pulmonary Disease Drugs Business Impact Assessment - COVID-19
      • 2.1.1 Global Chronic Obstructive Pulmonary Disease Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Chronic Obstructive Pulmonary Disease Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Chronic Obstructive Pulmonary Disease Drugs Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Chronic Obstructive Pulmonary Disease Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Chronic Obstructive Pulmonary Disease Drugs Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Chronic Obstructive Pulmonary Disease Drugs Market
    • 3.5 Key Manufacturers Chronic Obstructive Pulmonary Disease Drugs Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Chronic Obstructive Pulmonary Disease Drugs Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Inhalers
      • 1.4.2 Nebulizers
    • 4.2 By Type, Global Chronic Obstructive Pulmonary Disease Drugs Market Size, 2019-2021
      • 4.2.1 By Type, Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Chronic Obstructive Pulmonary Disease Drugs Price, 2020-2021

    5 Impact of Covid-19 on Chronic Obstructive Pulmonary Disease Drugs Segments, By Application

    • 5.1 Overview
      • 5.5.1 Emphysema
      • 5.5.2 Chronic Bronchitis
      • 5.5.3 Refractory Asthma
      • 5.5.4 Others
    • 5.2 By Application, Global Chronic Obstructive Pulmonary Disease Drugs Market Size, 2019-2021
      • 5.2.1 By Application, Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Chronic Obstructive Pulmonary Disease Drugs Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 AstraZeneca
      • 7.1.1 AstraZeneca Business Overview
      • 7.1.2 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.1.4 AstraZeneca Response to COVID-19 and Related Developments
    • 7.2 Boehringer Ingelheim
      • 7.2.1 Boehringer Ingelheim Business Overview
      • 7.2.2 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.2.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.2.4 Boehringer Ingelheim Response to COVID-19 and Related Developments
    • 7.3 GSK
      • 7.3.1 GSK Business Overview
      • 7.3.2 GSK Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.3.3 GSK Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.3.4 GSK Response to COVID-19 and Related Developments
    • 7.4 Novartis
      • 7.4.1 Novartis Business Overview
      • 7.4.2 Novartis Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.4.3 Novartis Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.4.4 Novartis Response to COVID-19 and Related Developments
    • 7.5 Teva Pharmaceuticals
      • 7.5.1 Teva Pharmaceuticals Business Overview
      • 7.5.2 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.5.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.5.4 Teva Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.6 Ache Laboratorios Farmaceuticos
      • 7.6.1 Ache Laboratorios Farmaceuticos Business Overview
      • 7.6.2 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.6.3 Ache Laboratorios Farmaceuticos Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.6.4 Ache Laboratorios Farmaceuticos Response to COVID-19 and Related Developments
    • 7.7 Almirall
      • 7.7.1 Almirall Business Overview
      • 7.7.2 Almirall Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.7.3 Almirall Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.7.4 Almirall Response to COVID-19 and Related Developments
    • 7.8 Aquinox Pharmaceuticals
      • 7.8.1 Aquinox Pharmaceuticals Business Overview
      • 7.8.2 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.8.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.8.4 Aquinox Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.9 Ario Pharma
      • 7.9.1 Ario Pharma Business Overview
      • 7.9.2 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.9.3 Ario Pharma Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.9.4 Ario Pharma Response to COVID-19 and Related Developments
    • 7.10 Asmacure
      • 7.10.1 Asmacure Business Overview
      • 7.10.2 Asmacure Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.10.3 Asmacure Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.10.4 Asmacure Response to COVID-19 and Related Developments
    • 7.11 Astellas Pharma
      • 7.11.1 Astellas Pharma Business Overview
      • 7.11.2 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.11.3 Astellas Pharma Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.11.4 Astellas Pharma Response to COVID-19 and Related Developments
    • 7.12 BioMarck Pharmaceuticals
      • 7.12.1 BioMarck Pharmaceuticals Business Overview
      • 7.12.2 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Quarterly Production and Revenue, 2020
      • 7.12.3 BioMarck Pharmaceuticals Chronic Obstructive Pulmonary Disease Drugs Product Introduction
      • 7.12.4 BioMarck Pharmaceuticals Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Chronic Obstructive Pulmonary Disease Drugs Supply Chain Analysis
      • 8.1.1 Chronic Obstructive Pulmonary Disease Drugs Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Chronic Obstructive Pulmonary Disease Drugs Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Chronic Obstructive Pulmonary Disease Drugs Distribution Channels
      • 8.2.2 Covid-19 Impact on Chronic Obstructive Pulmonary Disease Drugs Distribution Channels
      • 8.2.3 Chronic Obstructive Pulmonary Disease Drugs Distributors
    • 8.3 Chronic Obstructive Pulmonary Disease Drugs Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Chronic Obstructive Pulmonary Disease Drugs, including the following market information:
      Global Chronic Obstructive Pulmonary Disease Drugs Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva Pharmaceuticals, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, Asmacure, Astellas Pharma, BioMarck Pharmaceuticals, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Inhalers
      Nebulizers

      Based on the Application:
      Emphysema
      Chronic Bronchitis
      Refractory Asthma
      Others

      Buy now